Godavari Drugs reports flat FY26 results as revenue slips to ₹105.81 cr
The nano-cap pharmaceutical company saw annual revenue and profit decline slightly, though Q4 standalone revenue showed improvement.
— 1 earlier story on Godavari Drugs Ltd. →What's new
- FY26 revenue fell to ₹105.81 cr from ₹113.35 cr in FY25.
- Net profit for the year dropped to ₹4.09 cr from ₹4.38 cr.
- Q4 standalone revenue reached ₹33.16 cr, marking a sequential and year-on-year rise.
Why this matters
The results show a period of stagnation for the company. While the Q4 revenue uptick provides a minor positive, the annual decline in both top and bottom lines confirms a lack of growth momentum.
What we're watching
- Whether the Q4 revenue improvement signals a sustained recovery in FY27.
- Updates on the utilization of preferential issue proceeds.
- Management commentary on margin pressures affecting annual profitability.
The full read
Godavari Drugs closed FY26 with a modest decline in its financial metrics. Annual revenue slipped to ₹105.81 crore from ₹113.35 crore in the previous year, while net profit fell to ₹4.09 crore from ₹4.38 crore. Despite the annual contraction, the company recorded ₹33.16 crore in standalone revenue for Q4, showing both sequential and year-on-year growth. The filing remains a routine disclosure, covering standard board outcomes such as the appointment of cost auditors and the planning of the upcoming AGM. There were no surprises in the numbers, nor were there any shifts in guidance or strategy. The company also confirmed that its preferential issue proceeds were used as intended. For investors, the results confirm a period of flat performance for the nano-cap firm, with the Q4 revenue uptick serving as the only notable deviation from the broader annual trend.
Questions answered
- How did Godavari Drugs perform in FY26 compared to FY25?
- The company experienced a slight contraction in performance. Revenue fell to ₹105.81 crore from ₹113.35 crore, while net profit dipped to ₹4.09 crore from ₹4.38 crore.
- Was there any positive momentum in the final quarter?
- Yes, Q4 standalone revenue reached ₹33.16 crore, which represents an improvement on both a sequential and year-on-year basis.
- Did the company report any changes in its strategic direction?
- No. The filing was a standard financial disclosure and included only routine administrative approvals like the appointment of auditors and the scheduling of the AGM.
- Is there any concern regarding the company's use of capital?
- The company confirmed there was no deviation in the use of proceeds from its preferential issue.
Story so far
All notes on GODAVARI →- 27 May 2026 · 4:57 PM IST Godavari Drugs reports flat FY26 results as revenue slips to ₹105.81 cr
- today Godavari Drugs revenue slips to ₹105.81 cr in FY26